Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

ARNA 4.20 -0.04 (-0.94%)
price chart
Arena Pharmaceuticals Inc (NASDAQ:ARNA) in Focus
[PRNewswire] Arena Pharmaceuticals Inc (NASDAQ:ARNA)(TREND ANALYSIS) provided a corporate update and reported financial results for the first quarter ended March 31, 2015.
Arena: Belviq Sales Flattening Out - Is It Sector Saturation? (ARNA)  Seeking Alpha
Arena Pharmaceuticals, Inc. Price Target Update  The Daily Rover
Arena Pharmaceuticals Inc.'s Plan to Win the Obesity Drug War
Considering the number of obese Americans -- 35% of the entire U.S. adult population, according to the Centers for Disease Control and Prevention -- obesity-drug makers haven't come close to reaching their potential.
Why These Three Stocks Active Today? Kohl's Corp. (NYSE:KSS), Arena ...
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Biotech Equities Technical Study -- Gilead Sciences, Celgene, Novavax, Arena ...
Although Arena Pharmaceuticals Inc.'s stock has lost 8.41% in the last one month, it has advanced 0.24% in the previous three trading sessions and 22.48% on YTD basis.
Needham Remains Neutral on Arena Pharmaceuticals, Inc. Following 1Q:15 ...
Needham's healthcare analyst Alan Carr weighed in today with an update on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), after the company reported first-quarter financial results and held a conference call last night to provide a corporate update.
Arena Pharmaceuticals: Belviq Rebounds But Needs Help (ARNA)
New prescription numbers for week ending April 17 have been released by IMS for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The week-to-week improvement in total prescriptions ((TRx)) was a nice bounce ...
Arena Pharmaceuticals In Good Shape Despite Flat Week In Prescriptions (ARNA)
Today, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented more details from a study of weight loss drug Belviq as an investigational agent for smoking cessation at the American Thoracic Society International Conference taking place in Denver, ...
Fall in love with these 4 stocks: Arena Pharmaceuticals (ARNA), Merrimack ...  Wall Street Observer
Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected
Arena Pharma is a Zacks Rank #3 (Hold) stock. The company's first quarter 2015 results were better-than-expected with Belviq sales as well as prescriptions improving on a sequential basis.
Arena Pharmaceuticals and Roivant Sciences Enter into Collaboration for ...  MarketWatch
Arena Beats The Street On A Mixed Bag  Seeking Alpha
Biotech Stocks You Should Dump - Plasmatech Biopharmaceuticals (PTBI ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -1.62% to finish last trading session at $4.24. The company, on May 11, 2015, announced financial results for the first quarter ended March 31, 2015.
Will Arena Pharmaceuticals (ARNA) Surprise this Earnings?
Arena Pharmaceuticals, Inc. (ARNA - Analyst Report) is expected to report first-quarter 2015 results on May 11. Arena Pharma's performance has been mostly disappointing in 2014 with the company missing earnings expectations in three of the last four ...
Will Arena Pharmaceuticals (ARNA) Surprise this Earnings? - Analyst Blog  Nasdaq